Agreement to acquire TESARO
On 3 December 2018 we announced our agreement to acquire TESARO, an oncology-focused company based in the US for approximately $5.1bn.
Transformative potential from PARPs
Our strong belief is that PARP inhibitors are important medicines that have been under appreciated in terms of the impact they can have on cancer patients. PARP inhibitors have transformed the treatment of ovarian cancer and offer significant opportunities for use in the treatment of multiple cancer types.
Find out more
Keep up to date with our news and recent announcements
Our Pharmaceuticals business is made up of innovative medicines and holds leading market positions in respiratory disease and HIV.
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
We research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.